ANTX: חוב לטווח קצר של החברה AN2 Therapeutics Inc

Total short-term liabilities demonstrate the current financial burden of AN2 Therapeutics, Inc. (ANTX), where 0.00 represents the current metric value. Business stability relies on substantial grants and liquid reserves, eliminating the need for borrowing. However, a high burn rate and challenges in recruiting patients for rare pathologies create risks. Prospects depend on the success of clinical trials for innovative antibiotics targeting resistant bacteria.

Short-term debt measures the total liabilities with a maturity of up to one year, allowing for an assessment of liquidity and the risk of loan overpayment during external shocks. The trend in short-term borrowing levels reflects the intensity of working capital procurement, which is critical for AN2 Therapeutics (ANTX) when financing the development of antibiotics against resistant bacteria in US research centers.